PL2791177T3 - Cząsteczki przeciwciała wiążące trombinę i ich zastosowania - Google Patents

Cząsteczki przeciwciała wiążące trombinę i ich zastosowania

Info

Publication number: PL2791177T3
Authority: PL; Poland
Prior art keywords: thrombin; antibody molecules; binding antibody; binding; molecules
Prior art date: 2011-12-14

Application number

PL12806641T

Other languages

English (en)

Inventor

James Andrew Huntington

Trevor Baglin

Jonathan Langdown

Original Assignee

Janssen Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-14

Filing date

2012-12-14

Publication date

2018-03-30

2012-12-14 Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.

2018-03-30 Publication of PL2791177T3 publication Critical patent/PL2791177T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL12806641T 2011-12-14 2012-12-14 Cząsteczki przeciwciała wiążące trombinę i ich zastosowania PL2791177T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1121513.4A GB201121513D0 (en)	2011-12-14	2011-12-14	Thrombin-binding antibody molecules and uses thereof
EP12806641.2A EP2791177B1 (en)	2011-12-14	2012-12-14	Thrombin-binding antibody molecules and uses thereof
PCT/GB2012/053140 WO2013088164A1 (en)	2011-12-14	2012-12-14	Thrombin-binding antibody molecules and uses thereof

Publications (1)

Publication Number	Publication Date
PL2791177T3 true PL2791177T3 (pl)	2018-03-30

Family

ID=45560465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12806641T PL2791177T3 (pl)	2011-12-14	2012-12-14	Cząsteczki przeciwciała wiążące trombinę i ich zastosowania

Country Status (34)

Country	Link
US (5)	US9518129B2 (pl)
EP (2)	EP3275903A1 (pl)
JP (2)	JP6216954B2 (pl)
KR (1)	KR102114506B1 (pl)
CN (2)	CN104053673B (pl)
AU (2)	AU2012351858B2 (pl)
BR (1)	BR112014014605A2 (pl)
CA (1)	CA2856656C (pl)
CO (1)	CO7101192A2 (pl)
CY (1)	CY1119599T1 (pl)
DK (1)	DK2791177T3 (pl)
ES (1)	ES2642718T3 (pl)
GB (1)	GB201121513D0 (pl)
HK (1)	HK1246326A1 (pl)
HR (1)	HRP20171775T1 (pl)
HU (1)	HUE034793T2 (pl)
IL (1)	IL232797B (pl)
LT (1)	LT2791177T (pl)
ME (1)	ME02901B (pl)
MX (2)	MX376876B (pl)
MY (1)	MY170980A (pl)
NO (1)	NO2791177T3 (pl)
PE (2)	PE20190171A1 (pl)
PH (1)	PH12014501169B1 (pl)
PL (1)	PL2791177T3 (pl)
PT (1)	PT2791177T (pl)
RS (1)	RS56510B1 (pl)
RU (2)	RU2017144629A (pl)
SG (1)	SG11201402560WA (pl)
SI (1)	SI2791177T1 (pl)
SM (1)	SMT201700580T1 (pl)
UA (1)	UA116531C2 (pl)
WO (1)	WO2013088164A1 (pl)
ZA (1)	ZA201403836B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9518128B2 (en)	2011-12-14	2016-12-13	Janssen Pharmaceuticals, Inc.	Thrombin-binding antibody molecules
GB201121513D0 (en)	2011-12-14	2012-01-25	Cambridge Entpr Ltd	Thrombin-binding antibody molecules and uses thereof
GB201310949D0 (en) *	2013-06-19	2013-07-31	Cambridge Entpr Ltd	Binding Motif
GB201310948D0 (en) *	2013-06-19	2013-07-31	Cambridge Entpr Ltd	Screening methods
CN107043423B (zh) *	2016-02-05	2021-02-26	江苏恒瑞医药股份有限公司	凝血酶抗体、其抗原结合片段及医药用途
RU2018129180A (ru) *	2016-02-05	2020-03-05	Цзянсу Хэнжуй Медицин Ко., Лтд.	Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение
WO2018081534A1 (en) *	2016-10-28	2018-05-03	President And Fellows Of Harvard College	Assay for exo-site binding molecules
WO2019030706A1 (en)	2017-08-10	2019-02-14	Janssen Pharmaceutica Nv	ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en)	2017-08-16	2019-02-21	Janssen Pharmaceutica Nv	ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) *	2018-06-25	2020-01-02	Janssen Pharmaceutica Nv	Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989011297A1 (en) *	1988-05-27	1989-11-30	Centocor, Inc.	Freeze-dried formulation for antibody products
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5240913A (en)	1989-08-18	1993-08-31	Biogen, Inc.	Inhibitors of thrombin
US5196404B1 (en)	1989-08-18	1996-09-10	Biogen Inc	Inhibitors of thrombin
EP0534988A1 (en)	1990-05-10	1993-04-07	Cetus Corporation	Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5443827A (en) *	1993-05-03	1995-08-22	President And Fellows Of Harvard College	Fibrin-targeted inhibitors of thrombin
WO1995017907A1 (en) *	1993-12-27	1995-07-06	Hamilton Civic Hospitals Research Development, Inc.	Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en)	1996-06-29	1996-08-28	Thrombosis Res Inst	Thrombin inhibitors
US5985833A (en)	1996-09-17	1999-11-16	Wisconsin Alumni Research Foundation	Thrombin inhibitor
WO2001000667A2 (en)	1999-06-29	2001-01-04	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-thrombin peptide from anopheles albimanus salivary gland
CA2378473A1 (en) *	1999-07-23	2001-02-01	The Regents Of The University Of California	Modulation of platelet activation
CN100339132C (zh) *	2000-05-15	2007-09-26	史密丝克莱恩比彻姆公司	抗血栓剂
AU2001286900A1 (en)	2000-08-31	2002-03-13	Cor Therapeutics, Inc.	Therapeutics and diagnostics based on a novel signal transduction system in platelets
WO2003003988A2 (en) *	2001-07-06	2003-01-16	Oregon Health & Science University	Peptides which modulate blood coagulation and methods of use thereof
TWI338009B (en) *	2001-10-29	2011-03-01	Genentech Inc	Antibodies for inhibiting blood coagulation and methods of use thereof
MEP0208A (xx)	2005-08-26	2010-02-10	Archemix Corp	Aptameri koji vezuje trombin sa visokim afininitetom
WO2007106893A2 (en)	2006-03-15	2007-09-20	Emory University	Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
GB0711779D0 (en)	2007-06-18	2007-07-25	Univ Singapore	Thrombin inhibitor
WO2009154461A1 (en)	2008-06-19	2009-12-23	Prothix Bv	Use of anti-factors xi antibodies for prevention of thrombus formation
US20110275701A1 (en) *	2008-09-18	2011-11-10	Archemix Corp.	Anti-thrombin aptamer formulations and methods for use
JP6253578B2 (ja)	2011-07-22	2017-12-27	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
US9518128B2 (en)	2011-12-14	2016-12-13	Janssen Pharmaceuticals, Inc.	Thrombin-binding antibody molecules
GB201121513D0 (en) *	2011-12-14	2012-01-25	Cambridge Entpr Ltd	Thrombin-binding antibody molecules and uses thereof

2011
- 2011-12-14 GB GBGB1121513.4A patent/GB201121513D0/en not_active Ceased
2012
- 2012-12-14 HU HUE12806641A patent/HUE034793T2/en unknown
- 2012-12-14 DK DK12806641.2T patent/DK2791177T3/en active
- 2012-12-14 RU RU2017144629A patent/RU2017144629A/ru unknown
- 2012-12-14 NO NO12806641A patent/NO2791177T3/no unknown
- 2012-12-14 WO PCT/GB2012/053140 patent/WO2013088164A1/en not_active Ceased
- 2012-12-14 UA UAA201406892A patent/UA116531C2/uk unknown
- 2012-12-14 PE PE2018002007A patent/PE20190171A1/es unknown
- 2012-12-14 LT LTEP12806641.2T patent/LT2791177T/lt unknown
- 2012-12-14 CN CN201280061294.8A patent/CN104053673B/zh not_active Expired - Fee Related
- 2012-12-14 MY MYPI2014001764A patent/MY170980A/en unknown
- 2012-12-14 CN CN201711384542.3A patent/CN107936119B/zh not_active Expired - Fee Related
- 2012-12-14 AU AU2012351858A patent/AU2012351858B2/en not_active Ceased
- 2012-12-14 EP EP17177235.3A patent/EP3275903A1/en not_active Withdrawn
- 2012-12-14 SG SG11201402560WA patent/SG11201402560WA/en unknown
- 2012-12-14 PT PT128066412T patent/PT2791177T/pt unknown
- 2012-12-14 CA CA2856656A patent/CA2856656C/en active Active
- 2012-12-14 RS RS20171073A patent/RS56510B1/sr unknown
- 2012-12-14 EP EP12806641.2A patent/EP2791177B1/en active Active
- 2012-12-14 SM SM20170580T patent/SMT201700580T1/it unknown
- 2012-12-14 JP JP2014546649A patent/JP6216954B2/ja not_active Expired - Fee Related
- 2012-12-14 ME MEP-2017-243A patent/ME02901B/me unknown
- 2012-12-14 PL PL12806641T patent/PL2791177T3/pl unknown
- 2012-12-14 BR BR112014014605A patent/BR112014014605A2/pt not_active Application Discontinuation
- 2012-12-14 US US14/363,514 patent/US9518129B2/en not_active Expired - Fee Related
- 2012-12-14 SI SI201231145T patent/SI2791177T1/en unknown
- 2012-12-14 MX MX2018000197A patent/MX376876B/es unknown
- 2012-12-14 MX MX2014007170A patent/MX353281B/es active IP Right Grant
- 2012-12-14 HR HRP20171775TT patent/HRP20171775T1/hr unknown
- 2012-12-14 ES ES12806641.2T patent/ES2642718T3/es active Active
- 2012-12-14 RU RU2014124985A patent/RU2642276C2/ru active
- 2012-12-14 KR KR1020147019168A patent/KR102114506B1/ko not_active Expired - Fee Related
- 2012-12-14 PE PE2014000953A patent/PE20141706A1/es active IP Right Grant
2014
- 2014-05-26 PH PH12014501169A patent/PH12014501169B1/en unknown
- 2014-05-26 IL IL232797A patent/IL232797B/en active IP Right Grant
- 2014-05-26 ZA ZA2014/03836A patent/ZA201403836B/en unknown
- 2014-07-11 CO CO14150372A patent/CO7101192A2/es unknown
2016
- 2016-11-10 US US15/348,250 patent/US9988463B2/en active Active
2017
- 2017-08-30 JP JP2017165700A patent/JP6705785B2/ja not_active Expired - Fee Related
- 2017-11-14 CY CY20171101189T patent/CY1119599T1/el unknown
- 2017-12-01 AU AU2017268655A patent/AU2017268655B2/en not_active Ceased
2018
- 2018-05-08 HK HK18105913.3A patent/HK1246326A1/en unknown
- 2018-05-10 US US15/976,512 patent/US10287363B2/en not_active Expired - Fee Related
2019
- 2019-03-25 US US16/363,396 patent/US20190276558A1/en not_active Abandoned
2021
- 2021-06-10 US US17/344,577 patent/US20210371543A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3275903A1 (en)	2018-01-31
HUE034793T2 (en)	2018-02-28
DK2791177T3 (en)	2017-12-18
MY170980A (en)	2019-09-23
HRP20171775T1 (hr)	2017-12-29
SI2791177T1 (en)	2018-03-30
HK1246326A1 (en)	2018-09-07
NZ625386A (en)	2017-03-31
BR112014014605A2 (pt)	2017-06-13
MX2014007170A (es)	2015-04-17
PE20141706A1 (es)	2014-11-13
CN107936119A (zh)	2018-04-20
CN107936119B (zh)	2021-06-15
US20190276558A1 (en)	2019-09-12
CN104053673B (zh)	2018-01-12
SG11201402560WA (en)	2014-06-27
ES2642718T3 (es)	2017-11-17
PH12014501169A1 (en)	2014-09-08
PE20190171A1 (es)	2019-02-01
JP6705785B2 (ja)	2020-06-03
GB201121513D0 (en)	2012-01-25
PH12014501169B1 (en)	2014-09-08
US9518129B2 (en)	2016-12-13
EP2791177B1 (en)	2017-09-06
CA2856656C (en)	2021-01-19
NO2791177T3 (pl)	2018-02-03
AU2012351858A1 (en)	2014-06-12
AU2017268655B2 (en)	2019-05-09
UA116531C2 (uk)	2018-04-10
US9988463B2 (en)	2018-06-05
ME02901B (me)	2018-04-20
KR20140105556A (ko)	2014-09-01
MX376876B (es)	2025-03-07
US10287363B2 (en)	2019-05-14
CY1119599T1 (el)	2018-04-04
US20210371543A1 (en)	2021-12-02
RU2017144629A3 (pl)	2021-04-05
SMT201700580T1 (it)	2018-01-11
CN104053673A (zh)	2014-09-17
CO7101192A2 (es)	2014-10-31
EP2791177A1 (en)	2014-10-22
AU2012351858B2 (en)	2017-10-05
JP2018039798A (ja)	2018-03-15
IL232797B (en)	2018-07-31
RS56510B1 (sr)	2018-02-28
HK1202564A1 (en)	2015-10-02
CA2856656A1 (en)	2013-06-20
ZA201403836B (en)	2015-12-23
US20180334511A1 (en)	2018-11-22
LT2791177T (lt)	2017-11-27
WO2013088164A1 (en)	2013-06-20
JP6216954B2 (ja)	2017-10-25
US20140370008A1 (en)	2014-12-18
IL232797A0 (en)	2014-07-31
MX353281B (es)	2018-01-08
RU2642276C2 (ru)	2018-01-24
JP2015501830A (ja)	2015-01-19
RU2017144629A (ru)	2019-02-18
PT2791177T (pt)	2017-11-29
AU2017268655A1 (en)	2017-12-21
US20170066842A1 (en)	2017-03-09
RU2014124985A (ru)	2016-02-10
KR102114506B1 (ko)	2020-05-22

Publication	Publication Date	Title
IL281250A (en)	2021-04-29	Anti-PHF-tau antibodies and uses thereof
IL272831B (en)	2021-12-01	Meditops and Meditop binding antibodies and their use
ZA202000056B (en)	2021-06-30	Engineered microbe-targeting molecules and uses thereof
IL259436A (en)	2018-07-31	Antibodies against 3angptl and their uses
DK2729170T3 (en)	2022-03-21	Antibody variants and uses thereof
IL232399A0 (en)	2014-06-30	Anti-2fgfr antibodies and their use
EP2756094A4 (en)	2015-05-06	ANTI-B7-H4 ANTIBODIES AND USES THEREOF
ZA201401843B (en)	2015-07-29	Antibodies against tl1a and uses thereof
IL231846A0 (en)	2014-05-28	Antibodies against c-met and their uses
IL232778B (en)	2020-09-30	Antibodies against pd-l1 and uses thereof
ZA201403836B (en)	2015-12-23	Thrombin-binding antibody molecules and uses thereof
PL3453723T3 (pl)	2022-01-03	Przeciwciała anty-asic1 i ich zastosowania
GB201219487D0 (en)	2012-12-12	Anti-S100A4 antibody molecules and their uses
GB201015790D0 (en)	2010-10-27	Thrombin-binding antibody molecules and uses thereof
GB201117182D0 (en)	2011-11-16	Anti-notch antibody molecules and uses thereof
GB201208372D0 (en)	2012-06-27	Antibodies and uses thereof